2018
DOI: 10.1007/s12178-018-9500-5
|View full text |Cite
|
Sign up to set email alerts
|

New Innovations in the Treatment of PJI and Biofilms—Clinical and Preclinical Topics

Abstract: Innovative treatment strategies of bacterial and biofilm infections revolve around (a) augmenting current therapies, such as improving the delivery and efficiency of conventional antibiotics and enhancing the efficacy of antiseptics and (b) administrating completely new therapeutic modalities, such as using immunotherapy, nanoparticles, lytic bacteriophages, photodynamic therapy, novel antibiotics, and antimicrobial peptides. Several promising treatment strategies for PJI are available to be tested further. Th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
43
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 41 publications
(44 citation statements)
references
References 88 publications
1
43
0
Order By: Relevance
“…Another common possibility, though particularly in chronic PJI, of negative cultures is the presence of biofilms, where the need for a different type of culture may require procedures for accurate diagnosis, such as sonication [39] [40].…”
Section: Discussionmentioning
confidence: 99%
“…Another common possibility, though particularly in chronic PJI, of negative cultures is the presence of biofilms, where the need for a different type of culture may require procedures for accurate diagnosis, such as sonication [39] [40].…”
Section: Discussionmentioning
confidence: 99%
“…Against S. aureus biofilm, rifampicin is the most common partner drug of effective combinations which were demonstrated in vitro and in vivo [ 34 , 100 ]. New antibiotics, such as oritavancin, have to deal with MRSA and vancomycin-resistant S. aureus , and also with intracellular bacteria—i.e., internalized bacteria in host cells—as rifampicin does, in order to show a better bacterial burden clearance [ 64 , 101 , 102 ]. To enhance these results, new antibiofilm molecules should probably be tested in combination with a classic antibiotic such as rifampicin in order to look for synergistic effects and act against all types of metabolism activities.…”
Section: Emergent Antibiofilm Strategies In Periprosthetic Joint Imentioning
confidence: 99%
“…AMPs are also promising because their activity as antibiofilm molecules can be independent of their activity against planktonic bacteria [ 88 ]. Associated with their low cytotoxicity and their activity against MRSA biofilm in vitro and in vivo, these characteristics arise in AMPs as serious candidates to investigate [ 101 , 105 ]. They also showed efficiency against slow-growing or dormant bacteria [ 106 ].…”
Section: Emergent Antibiofilm Strategies In Periprosthetic Joint Imentioning
confidence: 99%
“…Nonetheless, these implants are nonfunctional and do not articulate within a weight‐bearing joint. A murine model that utilizes a load‐bearing implant to effectively mimic the periprosthetic environment would be an ideal preclinical platform for basic scientists conducting orthopaedic research aimed at improving implant longevity 12‐16,21 . This approach has been attempted previously: Carli et al 14 described a model of PJI in the mouse knee; Jie et al 13 summarized several animal models of PJI in the knee, and; Powers et al 21 described a rat model of cemented total hip replacement.…”
Section: Introductionmentioning
confidence: 99%